Background. Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and in animal studies. Several small case series suggest that linezolid is poorly tolerated because of the side effects of anemia/thrombocytopenia and peripheral neuropathy. To characterize our clinical experience with linezolid, the California Department of Public Health Tuberculosis Control Branch's Multidrug-Resistant Tuberculosis (MDR-TB) Service reviewed cases in which the MDR-TB treatment regimens included linezolid therapy.
Linezolid, the first oxazolidinone approved for clinical use, has shown good activity against drug-resistant strains of Mycobacterium tuberculosis, both in vitro and in animal studies [1] [2] [3] . Linezolid is rapidly and extensively absorbed after oral dosing [4] . It readily distributes to well-perfused regions of the body, penetrates well into bronchoalveolar tissues, and acts by inhibiting protein synthesis at an early stage of translation [5] . Recent case series have reported clinical and radiographic improvement among patients with multidrugresistant tuberculosis (MDR-TB) whose treatment reg-imens included linezolid and for whom no acceptable alternative existed among other available drugs [6, 7] . Moreover, the rapid lowering of the bacillary load observed with the addition of linezolid among patients with MDR-TB with fluoroquinolone and/or aminoglycoside resistance [8] and patients receiving failing regimens suggests promising efficacy [9] . Linezolid's safety and tolerability are limited by the dose-and durationdependent occurrence of reversible myelosuppression and peripheral and optic neuropathy [10] [11] [12] . Despite these toxicities, cures have been reported among patients with MDR-TB treated with a linezolid-containing regimen [7, 13] . Published clinical experience with linezolid and MDR-TB has generally been limited by small sample sizes. A larger series may provide additional information on linezolid's role in treating drugresistant tuberculosis. We report on the California experience with linezolid in 30 patients with MDR-TB during a period of 5 years.
California reports 30-40 patients with MDR-TB and 0-4 patients with extensively drug-resistant tuberculosis (XDR-TB) annually. The California Department of Public Health Tuberculosis Control Branch's MDR-TB Service provides clinical consultation and technical expertise to local health jurisdictions to manage these challenging tuberculosis cases. To further characterize linezolid's safety, tolerability, and long-term treatment outcomes, the MDR-TB Service conducted a retrospective record review of patients whose regimens included linezolid.
MATERIALS AND METHODS
All MDR-TB cases in California with MDR-TB Service consultation that were treated with linezolid as part of an MDR-TB regimen from 1 January 2003 through 31 December 2007 were reviewed. Data review was censured on 31 December 2008.
All patients received linezolid as part of an expanded tuberculosis treatment regimen, tailored to the susceptibility results of each isolate and given by directly observed therapy throughout treatment. Treatment duration varied but was a minimum of 18 months. Treatment regimens included linezolid and у3 second-line companion drugs selected according to individual drug history and recent susceptibility results. Linezolid was administered orally at a dosage of 600 mg daily to all but 2 patients. One patient received 450 mg of linezolid daily, and the other received 600 mg 3 times a week, adjusted for body weight !40 kg. Treatment regimens also included vitamin B6 at a dosage of 50-100 mg daily, to reduce the risk of hematologic toxicity.
We abstracted state tuberculosis registry records and individual case data maintained as part of the MDR-TB Service, after personal identifiers were removed. Data included patient demographic characteristics and comorbid conditions; clinical, radiographic, and microbiological characteristics; serial sputum testing and culture results; treatment regimens, durations, and outcomes; and regimen toxicity and tolerability. We examined the treatment outcome of linezolid-containing regimens by clinical and radiographic improvement and by sputum smear and culture conversion. We examined safety and tolerability of linezolid by reviewing monthly complete blood count data and monthly inquiries regarding neuropathy. Myelosuppression, peripheral neuropathy, and optic neuropathy were assessed as linezolid related for this analysis. We assessed anemia and thrombocytopenia as mild (hemoglobin level, 10.0-13.0 g/dL; platelet count, platelets/L), moderate (8.0-9.9 g/dL; 9 100-150 ϫ 10 platelets/L), or severe (!8.0 g/dL and 9 9 50-99 ϫ 10 ! 50 ϫ 10 platelets/L) [14] , according to observed hemoglobin and platelet levels. Because this study used routinely collected surveillance and treatment data without patient identifiers, institutional review board approval was not required. Data were analyzed using Excel, 2003 (Microsoft).
Standard definitions were used for MDR-TB (ie, tuberculosis with documented resistance to at least isoniazid and rifampin) and XDR-TB (ie, MDR-TB with additional resistance to any fluoroquinolone antibiotic and at least 1 of 3 injectable drugs: capreomycin, amikacin, or kanamycin) [15] . For pulmonary cases, cure was defined by at least 2 consecutive negative cultures and no positive culture during the last 18 months of treatment, including an end-of-treatment specimen. For extrapulmonary cases, cure was defined by treatment completion with no clinical or radiological signs of activity. An unsatisfactory outcome was defined as default, treatment failure, relapse, or death. Disease status. Of the 30 patients, 14 (47%) had a history of previous treatment for tuberculosis. Twenty-nine (97%) of the 30 patients had pulmonary disease. One patient had Pott disease. Of the 29 patients with pulmonary tuberculosis, 16 (55%) had cavitary changes noted on initial chest radiograph or chest computed tomography, and 21 (72%) had positive sputum-smear microscopy results at the time of MDR-TB diagnosis. Twenty-nine patients had positive cultures; the drugsusceptibility test results are shown in Table 1 . One patient had a positive result of sputum smear and had a molecular beacon test for isoniazid and rifampin resistance [16] performed on her clinical specimen, which showed the presence of katG and rpoB mutations, but her specimen was unable to be cultured. The median number of drugs to which the 29 culture-positive isolates were resistant was 5 (range, 2-13 drugs). Three (10%) of the 30 cases were XDR-TB.
RESULTS

Demographic characteristics.
Treatment. The median number of drugs used for MDR-TB treatment was 5, and each regimen included a fluoroquinolone and an injectable agent unless resistance was noted to these classes of drugs. Indications for using linezolid were failure of previous MDR-TB treatment regimen or presence of extensive drug resistance or inability to tolerate other secondline drugs. The mean duration of linezolid administration was 18.9 months (range, 1-28 months). Table 1 shows the specific drugs used in each case. One patient underwent a pneumonectomy in addition to his drug regimen. A second patient had extensive chest wall surgery for empyema necessitans.
Treatment outcomes. At data censure, 22 (73%) of the 30 patients had successfully completed therapy, with documented negative cultures for at least 18 months before the end of treatment, with 1 exception. That patient had 10 months of negative cultures before the end of treatment and has had follow-up for 3.5 years without relapse. Five patients (17%) are still receiving treatment. There were no deaths. Table 2 shows toxicities and treatment outcomes.
Only 3 (10%) of the patients had an unsatisfactory outcome.
Two patients defaulted. Of these, 1 refused to continue treatment after 27 weeks of therapy, because of intractable side effects. This patient had received previous treatment for tuberculosis in another country and had extensive fibrosis seen on chest radiograph, but only 1 sputum specimen of many obtained was positive for tuberculosis. He continues to be monitored at 6-month intervals without evidence of disease progression on radiograph and with negative sputum cultures. A second patient was lost to follow-up after 9.5 months of treatment. One patient had a treatment failure. This patient developed central line sepsis after ∼10 days of intravenous capreomycin treatment. She refused further injectable therapy and was then placed on a 5-drug, all-oral regimen that included linezolid and moxifloxacin. The culture converted to negative quickly, but subsequently, her radiograph findings worsened, and cultures reverted to positive after 22 months of treatment.
For the 29 patients with pulmonary disease, all achieved conversion of culture to negative. The median time to culture conversion was 7 weeks after the initiation of MDR-TB therapy (range, 0-50 weeks).
Of the 22 patients who completed therapy, none have relapsed, after a mean follow-up of 1.5 years (range, 0-3.5 years). The remaining 5 patients receiving treatment were doing well at the time of data censure.
Treatment toxicity. Of the 30 patients, 21 (70%) had no reported significant toxicity likely attributable to linezolid therapy. Three patients stopped linezolid therapy because of side effects.
At baseline, 7 patients had mild-to-moderate anemia documented. Despite all patients receiving vitamin B6 as part of their regimen, 2 patients developed symptomatic anemia (hemoglobin levels, 10.6 and 8.6 g/dL) with dyspnea on exertion and fatigue while receiving linezolid, one of whom had moderate anemia at baseline. In 1 case, use of erythropoietin allowed the patient to continue to receive linezolid. This patient had not been anemic at treatment initiation. One patient developed mild thrombocytopenia (platelet count, platelets/L). 9 150 ϫ 10 Despite these toxicities, no patients stopped linezolid treatment because of myelosuppression.
Peripheral neuropathy developed in 5 patients; for 1 of these patients, therapy with linezolid had to be discontinued after 5 months. This patient had poorly controlled diabetes. The remaining 4 patients were able to continue linezolid with careful monitoring of symptoms, with the plan to discontinue the drug if neuropathy progressed beyond the forefoot. In one instance, increasing the vitamin B6 dose from 150 mg to 200 mg appeared to resolve the neurologic complaints. Peripheral neuropathy did not resolve in the other 3 patients.
One patient developed visual loss secondary to optic neuropathy after 10 months of linezolid therapy. This patient also received rifabutin for 3 months. The patient developed worsening blurry vision and white spots in both visual fields. A neuro-ophthalmologic examination revealed findings consistent with linezolid-associated optic neuropathy. Following the immediate discontinuation of linezolid, visual acuity returned to normal over the course of 3-4 weeks. Linezolid was not restarted in this patient.
One additional patient developed severe, intractable diarrhea and nausea shortly after beginning linezolid, and the drug had to be discontinued because of these side effects, which resolved after discontinuation of linezolid. Lactic acidosis and serotonin syndrome, known toxicities of linezolid [17, 18] , were not seen in our study. Rash was noted in one patient, but after rechallenge with all drugs in the regimen, including linezolid, the patient was able to complete therapy.
DISCUSSION
Compared with patients with pansusceptible tuberculosis, patients with MDR-TB and XDR-TB have significantly worse short-and long-term outcomes because of the lack of potent bactericidal drugs, the lengthy treatment duration of 18-30 months, and the difficult-to-tolerate side effects and toxicities of second-line medications used for treatment. Mitnick et al [19] presented the most optimistic treatment outcome results, suggesting that patients with XDR-TB treated in a communitybased setting in Peru had a 60% cure rate.
Linezolid has been shown to be effective in the treatment of MDR-TB and XDR-TB in 5 case series [6-8, 13, 20] . However, several studies have found side effects and toxicities, primarily bone marrow suppression and peripheral and optic neuropathy, to be limiting factors in the use of linezolid. Park et al [6] report successful culture conversion in 8 HIV-negative patients but describe a high incidence of side effects even with a daily linezolid dose of 600 mg; 4 patients developed peripheral neuropathy, 2 developed optic neuropathy, and 1 developed anemia. Three patients discontinued treatment with linezolid, and 2 died of respiratory failure. The authors concluded that linezolid may be effective but is poorly tolerated. von der Lippe et al [7] reported a cohort of 10 patients with MDR-TB, 7 of whom developed significant side effects necessitating discontinuation of linezolid. Fortun et al [13] described successful treatment with linezolid for 5 patients with MDR-TB, but 4 patients developed severe anemia requiring blood transfusion at a dosage of 600 mg orally twice daily. In contrast, Condos et al [8] presented their findings for 7 patients with XDR-TB, showing initial culture conversion in all patients and a low incidence of hematologic and myelosuppressive side effects despite administration of the US Food and Drug Administration (FDA)-approved dosage of 600 mg orally twice a day (2 patients had peripheral neuropathy, and none had serious myelosuppressive side effects). Although 2 of 7 patients died, the authors concluded that linezolid is effective, safe, and tolerable and postulated that the difference in tolerability in their case series may be attributable to close follow-up in a hospital or specialized tuberculosis unit setting. Migliori et al [20] reported 85 patients with MDR-TB and XDR-TB in Germany who were treated with linezolid. Thirty-two percent required discontinuation of treatment because of side effects. Discontinuation was significantly more frequent among patients receiving the 600-mg twice-daily dose.
The linezolid minimum inhibitory concentration (MIC) reported by the pharmaceutical company (Pfizer) for M. tuberculosis is 1 mg/mL. A cumulative weekly target area under the curve (AUC) of 350-700 mgϫh/mL is desired, which is based on the AUC/MIC ratio for gram-positive bacteria. For 7 daily doses of linezolid per week, the cumulative doses achieved an AUC/MIC ratio of 999 per week, which was above the desired target. On the basis of these data, we postulated that linezolid at a dosage of 600 mg once daily should be effective, with less toxicity.
Our case series is the largest from the United States on the use of linezolid-containing regimens for treatment of MDR-TB. We have reported on 30 patients receiving linezolid therapy at a dosage of 600 mg once daily (2 received intermittent or lower-dose therapy because of low body weight). Of the 30 patients, 22 successfully completed treatment. Among patients who completed treatment, there was no relapse during a mean follow-up of 1.5 years. All 29 patients with pulmonary tuberculosis achieved culture conversion, at a median time of 7 weeks. Five additional patients continued to receive treatment and were tolerating linezolid well at data censure. Two patients defaulted, and one experienced treatment failure, with an isolate with the same susceptibility pattern as the initial episode of MDR-TB. Linezolid discontinuation was necessary for only 3 patients: 1 because of progressive peripheral neuropathy, 1 because of onset of visual impairment from optic neuropathy that resolved after discontinuation of linezolid, and 1 because of intractable diarrhea that resolved after discontinuation of linezolid. Interestingly, 4 of 5 patients with peripheral neuropathy were able to continue linezolid, and myelosuppression, noted in only 2 patients, did not result in discontinuation of the medication. One patient with anemia was treated with erythropoietin, and one patient with thrombocytopenia was monitored closely. Both completed therapy with linezolid.
The low proportion of rate-limiting side effects and toxicities in our case series, in contrast to that in other reports, is likely multifactorial. First, we used a total daily dose of linezolid (600 mg) lower than the FDA-approved dose (1200 mg in 2 divided doses) for gram-positive organisms, which was used in most other MDR-TB case series. Second, the addition of vitamin B6 may have mitigated the bone marrow toxicity observed in other case series [21, 22] . Third, the use of colony-stimulating factors may be an effective adjunctive therapy in cases of anemia and may allow for continued treatment with linezolid if cost is not prohibitive. Fourth, HIV infection may predispose to peripheral neuropathy and myelosuppression, and none of our patients were known to be infected with HIV. Lastly, closely monitoring toxicities with ongoing expert consultation, rather than immediately discontinuing linezolid, may be helpful because most patients in our series did not have worse or escalating toxicities on continued therapy. This is an especially important point to emphasize as there are so few efficacious medications for the treatment of MDR-TB and XDR-TB. Managing side effects, while continuing the treatment regimen, is a very important principle in the treatment of these extremely difficult cases. Also, the linezolid side effect profile, although serious, has the advantage of infrequently causing gastrointestinal complaints and can often be added successfully when other second-line drugs used in MDR-TB treatment cannot be tolerated because of gastrointestinal problems.
There are several limitations to our study. First, although HIV status was not documented in every case, there were no known HIV-infected patients. It will be important to study linezolid tolerability and efficacy in an HIV-infected population. Second, since 53% of patients in our series did not report previous treatment for tuberculosis, this may have contributed to the good outcomes we found. Third, the decision to initiate linezolid treatment was sometimes made by a local health jurisdiction before consultation; therefore, there were not uniform criteria for use of the drug.
The optimal dose of linezolid that maximizes efficacy while minimizing toxicity remains to be defined. Our findings suggest that linezolid at a dosage of 600 mg once daily is well tolerated and appears to be an effective adjunctive medication in a treatment regimen tailored to susceptibility results for patients with complicated MDR-TB and XDR-TB with few other alternative treatment strategies.
Linezolid should be considered for use as an adjunct to the MDR-TB treatment regimen for patients with any of the following: XDR-TB; MDR-TB isolates resistant to all first-line drugs, a fluoroquinolone, or an injectable agent; extensive disease observed on chest radiograph or a high bacillary load as evidenced by bacteriologic studies; rapidly progressive and/or disseminated MDR-TB; or rapid amplification of drug resistance over time. The duration of treatment with linezolid is dependent on multiple factors, such as patient response, tolerability, and cost. We recommend the use of linezolid for the full duration of treatment if tolerated.
While receiving linezolid, patients should be closely monitored for signs or symptoms of bone marrow toxicity and peripheral and optic neuropathy. Bone marrow toxicity can be monitored with a complete blood count measured before starting and monthly throughout treatment, and neuropathy can be monitored by a monthly examination. Both should be com-plemented by patient education about side effects. Patients should also be cautioned to report any adverse side effects while receiving linezolid, especially visual changes or sudden loss of vision. Vitamin B6 should be coadministered with linezolid.
CONCLUSION
We have found linezolid to be an effective addition to the armamentarium of drugs available to treat MDR-TB and XDR-TB. Efficacy was excellent as part of an optimized MDR-TB or XDR-TB regimen, with very acceptable toxicity. A randomized study of outcomes with linezolid treatment should be done.
